FGF19: A Potential Drug Target and Biomarker (G9965)

Target Name: FGF19

NCBI ID: G9965

FGF19

Other Name(s): FGF-19 | fibroblast growth factor 19 | Fibroblast growth factor 19 | FGF19_HUMAN

FGF19: A Potential Drug Target and Biomarker

FGF19, also known as filemin, is a protein that is expressed in various tissues throughout the body, including the liver, pancreas, and skin. It is a member of the FGF family, which is known for its role in the development and maintenance of tissues. In recent years, researchers have become increasingly interested in FGF19 due to its potential as a drug target and biomarker.

The FGF19 gene was first identified in the late 1990s by researchers at the University of California, San Diego. They found that the gene was expressed in a variety of tissues, including the liver, pancreas, and skin. The FGF19 protein is made up of 19 amino acid residues and has a predicted molecular weight of 20.4 kDa.

FGF19 has been shown to play a role in the development and maintenance of tissues. For example, studies have shown that FGF19 is involved in the development of new blood vessels in the liver. It has also been shown to be involved in the development of new skin tissue and has been shown to play a role in the regulation of cell growth and differentiation.

FGF19 has also been shown to be involved in the development of certain diseases. For example, studies have shown that high levels of FGF19 are associated with the development of certain types of cancer, including liver cancer and pancreatic cancer. Additionally, FGF19 has been shown to be involved in the development of certain autoimmune diseases, such as rheumatoid arthritis and psoriasis.

Due to its potential as a drug target, FGF19 has become a focus of research in recent years. Researchers have been interested in finding small molecules that can inhibit FGF19 activity and prevent the development of certain diseases. This has led to the development of a number of potential drug compounds that have been shown to be effective in animal models.

In addition to its potential as a drug target, FGF19 has also been shown to be a potential biomarker. Researchers have been interested in using FGF19 as a marker for certain diseases, such as cancer. This is because FGF19 is often expressed at higher levels in tissues that are affected by these diseases, making it a potentially reliable indicator of the presence of these diseases.

One of the challenges in studying FGF19 is its complex structure. FGF19 is a member of the FGF family, which is known for having a highly conserved sequence. This makes it difficult to identify small molecules that can inhibit FGF19 activity. However, researchers have been successful in identifying a number of potential drug compounds that have been shown to be effective in animal models.

In addition to its potential as a drug target and biomarker, FGF19 is also of interest to researchers because of its potential role in the development of certain diseases. Studies have shown that FGF19 is involved in the development of new blood vessels in the liver and has been shown to play a role in the regulation of cell growth and differentiation. This makes it an potentially useful target for the development of new treatments for certain diseases.

Overall, FGF19 is a protein that has garnered a great deal of interest in recent years due to its potential as a drug target and biomarker. While more research is needed to fully understand its role in the development and maintenance of tissues, its potential as a drug target and biomarker is a promising area of study.

Protein Name: Fibroblast Growth Factor 19

Functions: Involved in the suppression of bile acid biosynthesis through down-regulation of CYP7A1 expression, following positive regulation of the JNK and ERK1/2 cascades. Stimulates glucose uptake in adipocytes. Activity requires the presence of KLB and FGFR4

The "FGF19 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FGF19 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets